Provectus Announces Updated Results from Phase 1B Trial of PV-10 in Combination with KEYTRUDA® for Treatment of Advanced Melanoma at ASCO 2019
03 juin 2019 16h05 HE
|
Provectus Biopharmaceuticals Inc.
No safety concerns identified; no significant overlap of or unexpected toxicities65% overall ORR with 9% CR (RECIST 1.1) maintainedPreliminary PFS of 12.3 monthsChanges in T cell populations similar...
Provectus Announces Preliminary Results from Phase 1 Trial of PV-10 for Treatment of Metastatic Neuroendocrine Tumors at ASCO 2019
03 juin 2019 09h05 HE
|
Provectus Biopharmaceuticals Inc.
No safety concerns identified50% ORR and 83% disease control of injected lesionsStable Chromogranin A responses and quality of life scores for nearly all subjects KNOXVILLE, TN, June 03, 2019 ...